Skip to main content

Marina Closes Financing with Potential Value of $8.7M

Premium

Marina Biotech said this week that it has completed a previously announced financing to sell up to $8.7 million shares of common stock.

The company said it sold approximately 1.8 million shares of its common stock at $1.84 per share in an initial financing with gross proceeds of $3.3 million.

Investors taking part in the stock offering also received a subscription unit to purchase up to an additional 2.4 million shares at any time up to 16 months after the initial closing for no greater than $2.21 per share. This could yield as much as $5.4 million in additional gross proceeds.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.